News & Updates
Showing Pharmacy articles
Showing
Show Multimedia Only

Lorlatinib delivers long-term survival benefits in advanced ALK-positive NSCLC
08 Sep 2026
byStephen Padilla
First-line treatment with lorlatinib demonstrates long-term survival benefits in patients with advanced anaplastic lymphoma kinase (ALK)-positive nonsmall cell lung cancer (NSCLC), as shown in the 7-year update from the phase III CROWN study.
08 Sep 2026

Real-world study supports new therapeutics for BRAF-mutant metastatic CRC
07 Sep 2026
byAudrey Abella
A real-world study presented at ESMO GI 2026 shows that pembrolizumab immunotherapy and a combination regimen of encorafenib and cetuximab are associated with meaningful survival benefits in BRAF-mutant metastatic colorectal cancer (CRC).
07 Sep 2026

Injectable HIV Tx trumps daily pill in virally suppressed adolescents
04 Sep 2026
byAudrey Abella
The week-96 LATA trial results demonstrate the superiority of long-acting injectable (LAI) cabotegravir/rilpivirine (CAB/RPV) to tenofovir/lamivudine/dolutegravir (TLD) for maintaining virologic suppression in adolescents with HIV in sub-Saharan Africa.
04 Sep 2026






